Erik Thunnissen

List of Publications by Citations

126 papers	13,604 citations	47 h-index	116 g-index
129 ext. papers	16,680 ext. citations	5.7 avg, IF	5.6 L-index

#	Paper	IF	Citations
126	International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. *Journal of Thoracic Oncology*, **2011**, 6, 244-85	8.9	3178
125	Comprehensive genomic profiles of small cell lung cancer. *Nature*, **2015**, 524, 47-53	50.4	1061
124	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. *Nature Genetics*, **2012**, 44, 1104-10	36.3	919
123	Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. *Science Translational Medicine*, **2010**, 2, 62ra93	17.5	646
122	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. *Journal of Thoracic Oncology*, **2013**,	8.9	632
121	Management of lung nodules detected by volume CT scanning. *New England Journal of Medicine*, **2009**, 361, 2221-9	59.2	598
120	PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. *Journal of Thoracic Oncology*, **2018**, 13, 1302-1311	8.9	381
119	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. *Archives of Pathology and Laboratory Medicine*, **2018**, 142, 321-346	5	371
118	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. *Archives of Pathology and*	5	365
117	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. *Journal of Molecular Diagnostics*, **2013**, 15, 415-53	5.1	340
116	Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. *Archives of Pathology and Laboratory Medicine*, **2013**, 137, 668-84	5	287
115	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. *Journal of Thoracic Oncology*, **2018**, 13, 323-358	8.9	241
114	Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers. *Lancet Oncology, The*, **2014**, 15, 1342-50	21.7	201
113	The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. *Lung Cancer*, **2012**, 76, 1-18	5.9	171
112	EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2012**, 461, 245-57	5.1	168
111	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. *Journal of Molecular Diagnostics*, **2018**, 20, 129-159	5.1	165
110	Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. *Modern Pathology*, **2012**, 25, 1574-83	9.8	155

109	Testing for ROS1 in non-small cell lung cancer: a review with recommendations. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2016**, 469, 489-503	5.1	146
108	Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial. *European Respiratory Journal*, **2013**, 42, 1659-67	13.6	143
107	Characteristics of lung cancers detected by computer tomography screening in the randomized NELSON trial. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 187, 848-54	10.2	142
106	Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma. *Journal of Thoracic Oncology*, **2018**, 13, 1569-1576	8.9	140
105	Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. *Journal of Clinical Oncology*, **2014**, 32, 2780-7	2.2	136
104	Guidance for laboratories performing molecular pathology for cancer patients. *Journal of Clinical Pathology*, **2014**, 67, 923-31	3.9	128
103	Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer. *Oncotarget*, **2016**, 7, 1066-75	3.3	120
102	Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. *Archives of Pathology and Laboratory Medicine*, **2013**, 137, 685-705	5	117
101	Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. *Journal of Thoracic Oncology*, **2019**, 14, 377-407	8.9	114
100	Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group. *Thorax*, **2016**, 71, 177-84	7.3	114
99	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. *Journal of Thoracic Oncology*, **2020**, 15, 499-519	8.9	99
98	Development of [(11)C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status. *Clinical Cancer Research*, **2013**, 19, 183-93	12.9	90
97	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. *Journal of Thoracic Oncology*, **2020**, 15, 1409-1424	8.9	80
96	Rapid On-Site Evaluation of Endobronchial Ultrasound-Guided Transbronchial Needle Aspirations for the Diagnosis of Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society. *Archives of Pathology and Laboratory Medicine*, **2018**, 142, 253-262	5	79
95	Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin. *Clinical Cancer Research*, **2011**, 17, 2581-90	12.9	78
94	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. *Journal of Thoracic Oncology*, **2020**, 15, 709-740	8.9	77
93	The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases. *Journal of Thoracic Oncology*, **2017**, 12, 334-346	8.9	67
92	Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis. *Lung Cancer*, **2015**, 89, 255-61	5.9	66

91	Clinical features of large cell neuroendocrine carcinoma: a population-based overview. *European Respiratory Journal*, **2016**, 47, 615-24	13.6	66
90	Towards a close computed tomography monitoring approach for screen detected subsolid pulmonary nodules?. *European Respiratory Journal*, **2015**, 45, 765-73	13.6	65
89	Prognostic and predictive biomarkers in lung cancer. A review. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2014**, 464, 347-58	5.1	65
88	Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2017**, 470, 5-20	5.1	62
87	A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation. *Clinical Cancer Research*, **2013**, 19, 743-51	12.9	61
86	Guideline on the requirements of external quality assessment programs in molecular pathology. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2013**, 462, 27-37	5.1	59
85	CD44 and OTP are strong prognostic markers for pulmonary carcinoids. *Clinical Cancer Research*, **2013**, 19, 2197-207	12.9	57
84	Ex Vivo Artifacts and Histopathologic Pitfalls in the Lung. *Archives of Pathology and Laboratory Medicine*, **2016**, 140, 212-20	5	55
83	A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. *Journal of Thoracic Oncology*, **2020**, 15, 1599-1610	8.9	52
82	Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society. *Archives of Pathology and Laboratory Medicine*, **2018**, 142, 408-419	5	52
81	Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: Number 2 in the Series "Pathology for the clinician" Edited by Peter Dorfmüller and Alberto Cavazza. *European Respiratory Review*, **2017**, 26,	9.8	49
80	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. *Journal of Thoracic Oncology*, **2018**, 13, 413-425	8.9	48
79	KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA. *Journal of Molecular Diagnostics*, **2012**, 14, 247-55	5.1	47
78	Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients. *Clinical Cancer Research*, **2018**, 24, 1337-1343	12.9	44
77	Combined sputum hypermethylation and eNose analysis for lung cancer diagnosis. *Journal of Clinical Pathology*, **2014**, 67, 707-11	3.9	41
76	Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLC. *Journal of Thoracic Oncology*, **2018**, 13, 1222-1226	8.9	40
75	Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology. *Cellular Oncology (Dordrecht)*, **2014**, 37, 353-61	7.2	38
74	ALK Immunohistochemistry in NSCLC: Discordant Staining Can Impact Patient Treatment Regimen. *Journal of Thoracic Oncology*, **2016**, 11, 2241-2247	8.9	32

73	Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project. *Lung Cancer*, **2017**, 111, 143-149	5.9	31
72	Reproducibility of histopathological diagnosis in poorly differentiated NSCLC: an international multiobserver study. *Journal of Thoracic Oncology*, **2014**, 9, 1354-62	8.9	31
71	Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor. *Journal of Clinical Pathology*, **2015**, 68, 320-1	3.9	29
70	EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy. *Journal of Clinical Pathology*, **2011**, 64, 884-92	3.9	28
69	Correlation of immunohistochemical staining p63 and TTF-1 with EGFR and K-ras mutational spectrum and diagnostic reproducibility in non small cell lung carcinoma. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2012**, 461, 629-38	5.1	27
68	KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value. *Journal of Thoracic Oncology*, **2013**, 8, 1190-5	8.9	27
67	PD-L1 Antibody Comparison in Urothelial Carcinoma. *European Urology*, **2019**, 75, 538-540	10.2	26
66	PD-L1 IHC in NSCLC with a global and methodological perspective. *Lung Cancer*, **2017**, 113, 102-105	5.9	25
65	Quantification of PD-L1 Expression with F-BMS-986192 PET/CT in Patients with Advanced-Stage Non-Small Cell Lung Cancer. *Journal of Nuclear Medicine*, **2020**, 61, 1455-1460	8.9	25
64	Close Surveillance with Long-Term Follow-up of Subjects with Preinvasive Endobronchial Lesions. *American Journal of Respiratory and Critical Care Medicine*, **2015**, 192, 1483-9	10.2	24
63	EGFR mutation analysis in sputum of lung cancer patients: a multitechnique study. *Lung Cancer*, **2013**, 82, 38-43	5.9	24
62	The relevance of external quality assessment for molecular testing for ALK positive non-small cell lung cancer: results from two pilot rounds show room for optimization. *PLoS ONE*, **2014**, 9, e112159	3.7	24
61	Successful treatment of diffuse pulmonary lymphangiomatosis with bevacizumab. *Annals of Internal Medicine*, **2012**, 156, 839-40	8	24
60	The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. *Lung Cancer*, **2021**, 154, 161-175	5.9	24
59	New Subsolid Pulmonary Nodules in Lung Cancer Screening: The NELSON Trial. *Journal of Thoracic Oncology*, **2018**, 13, 1410-1414	8.9	23
58	Impact of delayed and prolonged fixation on the evaluation of immunohistochemical staining on lung carcinoma resection specimen. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2019**, 475, 191-199	5.1	23
57	Reproducibility of immunohistochemical scoring for epidermal growth factor receptor expression in non-small cell lung cancer: round robin test. *Archives of Pathology and Laboratory Medicine*, **2013**, 137, 1255-61	5	23
56	Is the sum of positive neuroendocrine immunohistochemical stains useful for diagnosis of large cell neuroendocrine carcinoma (LCNEC) on biopsy specimens?. *Histopathology*, **2019**, 74, 555-566	7.3	23

55	A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. *Lung Cancer*, **2019**, 131, 95-103	5.9	22
54	Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. *Journal of Thoracic Oncology*, **2018**, 13, 205-217	8.9	22
53	Pulmonary loose tumor tissue fragments and spread through air spaces (STAS): Invasive pattern or artifact? A critical review. *Lung Cancer*, **2018**, 123, 107-111	5.9	20
52	Negative NKX2-1 (TTF-1) as temporary surrogate marker for treatment selection during EGFR-mutation analysis in patients with non-small-cell lung cancer. *Journal of Thoracic Oncology*, **2012**, 7, 1522-7	8.9	19
51	Prolonged sampling of spontaneous sputum improves sensitivity of hypermethylation analysis for lung cancer. *Journal of Clinical Pathology*, **2012**, 65, 541-5	3.9	18
50	Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarraysPand cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort. *Modern Pathology*, **2020**,	9.8	18
49	Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC. *EJNMMI Research*, **2016**, 6, 10	3.6	17
48	Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3Pdeoxy-3P[□]fluorothymidine positron emission tomography. *PLoS ONE*, **2013**, 8, e63705	3.7	17
47	DNA hypermethylation analysis in sputum of asymptomatic subjects at risk for lung cancer participating in the NELSON trial: argument for maximum screening interval of 2 years. *Journal of Clinical Pathology*, **2017**, 70, 250-254	3.9	15
46	A de novo FLCN mutation in a patient with spontaneous pneumothorax and renal cancer; a clinical and molecular evaluation. *Familial Cancer*, **2013**, 12, 373-9	3	15
45	Correlation of ROS1 Immunohistochemistry With Fusion Status Determined by Fluorescence In Situ Hybridization. *Archives of Pathology and Laboratory Medicine*, **2020**, 144, 735-741	5	13
44	In compressed lung tissue microscopic sections of adenocarcinoma in situ may mimic papillary adenocarcinoma. *Archives of Pathology and Laboratory Medicine*, **2013**, 137, 1792-7	5	12
43	External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different. *Journal of Pathology: Clinical Research*, **2020**, 6, 138-145	5.3	12
42	Gross handling of pulmonary resection specimen: maintaining the 3-dimensional orientation. *Journal of Thoracic Disease*, **2019**, 11, S37-S44	2.6	11
41	Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction. *Journal of Proteomics*, **2019**, 196, 106-119	3.9	11
40	Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy. *British Journal of Cancer*, **2020**, 123, 392-402	8.7	11
39	Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2013**, 462, 547-56	5.1	11
38	A Population-Based Analysis of Application of WHO Nomenclature in Pathology Reports of Pulmonary Neuroendocrine Tumors. *Journal of Thoracic Oncology*, **2016**, 11, 593-602	8.9	9

37	RET Fluorescence In Situ Hybridization Analysis Is a Sensitive but Highly Unspecific Screening Method for RET Fusions in Lung Cancer. *Journal of Thoracic Oncology*, **2021**, 16, 798-806	8.9	9
36	Lung cancer biomarker testing: perspective from Europe. *Translational Lung Cancer Research*, **2020**, 9, 887-897	4.4	8
35	Comprehensive Hybrid Capture-Based Next-Generation Sequencing Identifies a Double ALK Gene Fusion in a Patient Previously Identified to Be False-Negative by FISH. *Journal of Thoracic Oncology*, **2017**, 12, e22-e24	8.9	7
34	Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?. *Lung Cancer*, **2015**, 89, 19-26	5.9	7
33	Trastuzumab and paclitaxel in patients (pts) with EGFR mutated non-small-cell lung cancer (NSCLC) that express HER2 after progression on EGFR TKI treatment.. *Journal of Clinical Oncology*, **2017**, 35, 9042-9042	2.2	7
32	Whole body PD-1 and PD-L1 PET with 89Zr-nivolumab and 18F- BMS-986192 in pts with NSCLC.. *Journal of Clinical Oncology*, **2017**, 35, e20047-e20047	2.2	7
31	Multicentre study on the consistency of PD-L1 immunohistochemistry as predictive test for immunotherapy in non-small cell lung cancer. *Journal of Clinical Pathology*, **2020**, 73, 423-430	3.9	7
30	A Population-Based Study of Outcomes in Surgically Resected T3N0 Non-Small Cell Lung Cancer in The Netherlands, Defined Using TNM-7 and TNM-8; Justification of Changes and an Argument to Incorporate Histology in the Staging Algorithm. *Journal of Thoracic Oncology*, **2019**, 14, 459-467	8.9	6
29	Genetic subtypes of large cell neuroendocrine carcinoma (LCNEC) to predict response to chemotherapy.. *Journal of Clinical Oncology*, **2017**, 35, 9061-9061	2.2	6
28	Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project. *Journal of Thoracic Oncology*, **2021**, 16, 990-1002	8.9	6
27	Clonality analysis of pulmonary tumors by genome-wide copy number profiling. *PLoS ONE*, **2019**, 14, e0223827	3.7	5
26	Pathologists should probably forget about kappa. Percent agreement, diagnostic specificity and related metrics provide more clinically applicable measures of interobserver variability. *Annals of Diagnostic Pathology*, **2020**, 47, 151561	2.2	4
25	Diagnostic challenges in survivors of early stage lung cancer. *Lung Cancer*, **2015**, 90, 212-6	5.9	3
24	Pulmonary adenocarcinoma histology. *Translational Lung Cancer Research*, **2012**, 1, 276-9	4.4	3
23	COVID-19: Histopathological correlates of imaging patterns on chest computed tomography. *Respirology*, **2021**, 26, 869-877	3.6	3
22	Staining Performance of ALK and ROS1 Immunohistochemistry and Influence on Interpretation in Non-Small-Cell Lung Cancer. *Journal of Molecular Diagnostics*, **2020**, 22, 1438-1452	5.1	2
21	Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples. *BMC Cancer*, **2020**, 20, 366	4.8	2
20	Reply to Letter "The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases.". *Journal of Thoracic Oncology*, **2017**, 12, e70-e71	8.9	2

19	Tumor size does not predict pathological complete response rates after pre-operative chemoradiotherapy for non-small cell lung cancer. *Acta Oncologica*, **2013**, 52, 676-8	3.2	2
18	Bronchioloalveolar adenocarcinoma and pulmonary langerhans cell histiocytosis in a patient with MUTYH-associated polyposis. *Journal of Clinical Oncology*, **2011**, 29, e188-90	2.2	2
17	An 82-year-old woman with small-cell lung cancer: relapse after 9 years or a new primary?. *Journal of Thoracic Oncology*, **2012**, 7, e3-5	8.9	2
16	Sorafenib and metformin in pretreated patients with stage IV non-small cell lung cancer with a KRAS mutation: A multicenter single arm phase II study.. *Journal of Clinical Oncology*, **2014**, 32, e19015-e19015	2.2	2
15	Are lung cysts in renal cell cancer (RCC) patients an indication for FLCN mutation analysis?. *Familial Cancer*, **2016**, 15, 297-300	3	1
14	In Reply. *Archives of Pathology and Laboratory Medicine*, **2019**, 143, 909-910	5	1
13	Detecting resistance in EGFR-mutated non-small-cell lung cancer after clonal selection through targeted therapy. *Personalized Medicine*, **2015**, 12, 63-66	2.2	1
12	The CAP-IASLC-AMP molecular testing guideline for the selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors.. *Journal of Clinical Oncology*, **2013**, 31, 11085-11085	2.2	1
11	Influence of preanalytical variables on performance of delta-like protein 3 (DLL3) predictive immunohistochemistry. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2021**, 478, 293-300	5.1	1
10	Morphologic Logic: "Filigree" and "Classical" Micropapillary Pattern Are Orientation-Dependent Views of the Same Lesion. *Journal of Thoracic Oncology*, **2020**, 15, e120-e121	8.9	1
9	RE: Spread Through Air Spaces (STAS) is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung. *Journal of Thoracic Oncology*, **2020**, 15, e116-e117	8.9	1
8	Polarization-sensitive optical coherence tomography in end-stage lung diseases: an ex vivo pilot study. *Biomedical Optics Express*, **2021**, 12, 6796-6813	3.5	1
7	Rebiopsy in TKI-resistance: A retrospective analysis.. *Journal of Clinical Oncology*, **2013**, 31, 8065-8065	2.2	0
6	The impact of a pathologist's personality on the interobserver variability and diagnostic accuracy of predictive PD-L1 immunohistochemistry in lung cancer.. *Lung Cancer*, **2022**, 166, 143-149	5.9	0
5	Tumor Atelectasis Gives Rise to a Solid Appearance in Pulmonary Adenocarcinomas on High-Resolution Computed Tomography. *JTO Clinical and Research Reports*, **2020**, 1, 100018	1.4	
4	Epidemiological and clinical aspects of lung cancer945-1003		
3	Applying biomarker testing to clinical practice in lung cancer. *Lung Cancer Management*, **2012**, 1, 145-154	2.6	
2	Diagnosis of atypical carcinoid can be made on biopsies > 4 mm and is accurate.. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2022**, 480, 587	5.1	

1	Prevalence and clinical correlation of programmed cell death 1 ligand (PD-L1) expression in patients with resected non-small cell lung cancer (NSCLC): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort.. *Journal of Clinical Oncology*, **2017**, 35, 8516-8516	2.2